About Author:
AJEET*
Department of Pharmaceutics
S. D. College of Pharmacy and Vocational Studies,
Muzaffarnagar, U.P. India Pin: 251001
*ajeet_pharma111@rediffmail.com

INTRODUCTION
Amongst the various routes of drug delivery, oral route is perhaps the most preferred to the patient and the clinician alike. However, peroral administration of drugs has disadvantages such as hepatic first pass metabolism and enzymatic degradation within the GI tract, that prohibit oral administration of certain classes of drugs especially peptides and proteins. Consequently, other absorptive mucosae are considered as potential sites for drug administration. Transmucosal routes of drug delivery (i.e., the mucosal linings of the nasal, rectal, vaginal, ocular, and oral cavity) offer distinct advantages over peroral administration for systemic drug delivery. These advantages include possible bypass of first pass effect, avoidance of presystemic elimination within the GI tract, and, depending on the particular drug, a better enzymatic flora for drug absorption.

GVK is a diversified enterprise having interests in Infrastructure (Power, Transportation and Urban Infrastructure), Services (Hotels, Life-sciences and Financial) and Manufacturing (Particle Boards, Resins and Chemicals).GVKBIO, providing an integrated platform of research services across the Pharma R&D & Contract Manufacturing valu

Troikaa mainly focuses on Novel Drug Delivery Systems (NDDS). The company firmly believes in providing superior therapeutic benefits by improvising the formulations through Innovative Technologies.
Six patents have been filed in various areas of drug delivery. To handle competition, Troikaa adopted various multifaceted strategies to help stand their ground in the competitive market. Another fact that helps us stand out is their high quality products.

“Recent acquisition of Indian generic drug companies by MNCs has increased fears that the price of low-cost generic drugs will rise in India. The buy-outs will reduce domestic availability of many essential medicines; point out an internal assessment of the health ministry, Government of India. It is ironic that despite India supplying quality generic drugs around the world, the country has concerns about sufficient domestic drug supply and vaccines security. With the increasing acquisition of Indian companies by overseas drug corporations, there is a pressing need to rethink India’s drug strategy”. This statement was released by government of India before few months. Now what global honchos think about India?

Find out Answers of GPAT 2012. ALL MODEL KEYS ARE AVAILABLE BELOW. Model Key of GPAT 2012

SET A

CSIR-Central Drug Research Institute, Lucknow is a premier R&D Institute under the aegis of the Council of Scientific and Industrial Research (CSIR), New Delhi which is an autonomous body under Department of Scientific and Industrial Research, Government of India.

"La Renon" is created out of passion to become a global healthcare company by offering World-class quality pharmaceutical products and services for various critical illnesses and diseases.

Sree Chitra Tirunal Institute for Medical Sciences & Technology (SCTIMST), Thiruvananthapuram is an Institute of National Importance  established by an Act  of the Indian Parliament  and  under the 2 administrative control of the Department of Science and Technology, Government of India.

GPAT-2012 PAPER

{Answers are on the end page of question Paper}

A global healthcare leader, Novartis has one of the most exciting product pipelines in the industry today. A pipeline of innovative medicines brought to life by diverse, talented and performance driven people. All of which makes them one of the most rewarding employers in their field.

Naprod’s vision is to become a world class player in oncology through excellence in innovation, discovery of new manufacturing processes / drug delivery mechanisms and consistently high quality of production. We commenced operations in 1994 with the inauguration of our ultra-modern facility for the production of generics and formulations for oncology and other therapeutic applications.

ABOUT AUTHORS:
YASWANTH ALLAMNENI^1*, NAVYA ALLAMNENI², R AMARNATH¹, T RAMASWAMY CHOWDARY¹, V SATYANARAYANA¹, K VENKATESWARA RAO^1
1Research and Development Department, Natco Pharma Limited, Kothur, Mahaboobnagar, Andhra Pradesh – 509228.
²Department of Pharmaceutical Technology, Narasaraopeta Institute of Pharmaceutical Sciences, Narasaraopeta, Guntur,
Andhra Pradesh, India.
*yaswanthallamneni@gmail.com

ABSTRACT
The main aim of this article was to review the development of ODTs, challenges in formulation, new ODT technologies and evaluation methodologies, suitability of drug candidates, and future prospects.Over the past three decades, orally disintegrating tablets (ODTs) have gained considerable attention as a preferred alternative to conventional tablets and capsules due to better patient compliance. ODTs are solid dosage forms containing medicinal substances which disintegrate rapidly, usually in a matter of seconds, when placed on the tongue. Orally disintegrating tablets are also called as orodispersible, quick disintegrating, mouth dissolving, fast disintegrating, rapid dissolving tablets, porous tablets, and rapimelts.Orally disintegrating systems have carved a niche amongst the oral drug delivery systems due to the highest component of compliance they enjoy in patients especially the geriatrics and pediatrics. However, of all the above terms, USP approved these dosage forms as ODTs.  These tablets are distinguished from conventional sublingual tablets, lozenges, and buccal tablets which require more than a minute to dissolve in the mouth. According to the recently issued draft guidance for Industry of orally disintegrating tablets, FDA specifically recommends that, in addition to the original definition for an ODT, ODTs be considered solid oral preparations that disintegrate rapidly in the oral cavity, with an in vitro disintegration time of approximately 30 sec or less according to the united states pharmacopoeia (USP) disintegration method or alternative. ODTs release drug in the mouth for absorption through local oromucosal tissues and through pregastric (e.g., oral cavity, pharynx, and oesophagus), gastric (i.e., stomach) and post gastric (e.g. .small and large intestines) segments of the gastrointestinal tract.

Rajasthan Drugs & Pharmaceuticals Ltd (RDPL) is profit making Central Public Sector Enterprise. The The Company was formed as a joint venture between Central Government with 51% equity share holding and Rajasthan State Industrial Development and Investment corporation Ltd (RIICO) with 49% equity share holding. Rajasthan Drugs and Pharmaceuticals ltd.(RDPL) was incorporated on 02.11.1978 with the objective to supply life saving and other essential drugs.

AKUMS DRUGS & PHARMACEUTICALS LTD is one of the most innovative, productive and research based pioneer organization of India having its registered office at Delhi and various plants in Haridwar, Uttrakhand

Krishna Institute of Medical Sciences (KIMS) welcomes you to the hi-tech hub of Hyderabad. Centrally located on Minister Road, KIMS is where personalised medicare meets modern technology.At KIMS the cream of specialists come together to fulfill a wide range of medical requirements.